Kyowa Kirin

Kyowa Kirin is a Japan-based global specialty pharmaceutical company best known for pioneering POTELLIGENT technology — a glycoengineering platform that enhances antibody-dependent cellular cytotoxicity by modifying the sugar structure of therapeutic antibodies — which emerged from foundational glycobiology research at Kyowa Hakko and Japanese national universities. The company operates research centers in San Francisco, Princeton, and Tokyo, maintaining academic partnerships with Osaka University's Immunology Frontier Research Center and RIKEN for next-generation antibody-drug conjugate and bispecific antibody programs. Kyowa Kirin funds investigator-initiated trials at major oncology centers across the US, Japan, and Europe, building a network of KOL relationships across hematology and nephrology. The company recruits from PhD programs in protein engineering, cancer immunology, and translational oncology at institutions including UC Berkeley, Tokyo University, and the University of Toronto.